About ARTMS
ARTMS is a company based in Vancouver (Canada) founded in 2013 was acquired by Telix Pharma in March 2024. ARTMS has raised $26.58 million across 5 funding rounds from investors including GF Securities, Telix Pharmaceuticals and Innovate BC. ARTMS operates in a competitive market with competitors including NorthStar Medical Radioisotopes, Niowave, Nanovista, Ground Fluor Pharmaceuticals and ATOMIC ALCHEMY, among others.
- Headquarter Vancouver, Canada
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$26.58 M (USD)
in 5 rounds
-
Latest Funding Round
$300 K (USD), Grant
Feb 24, 2021
-
Investors
GF Securities
& 4 more
-
Employee Count
Not available
-
Acquired by
Telix Pharma
(Mar 05, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of ARTMS
ARTMS has successfully raised a total of $26.58M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $300 thousand completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ARTMS
ARTMS has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include GF Securities, Telix Pharmaceuticals and Innovate BC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Startup accelerator firm backed by the British Columbia Government
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Tech & Life Sciences focused early stage VC firm investing in North America
|
Locked | Locked | Locked |
Investor details for ARTMS
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ARTMS
Investment portfolio details for ARTMS
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ARTMS
Detailed financials for ARTMS
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Artms Comparisons
Peer comparison for ARTMS
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ARTMS
ARTMS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NorthStar Medical Radioisotopes, Niowave, Nanovista, Ground Fluor Pharmaceuticals and ATOMIC ALCHEMY, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of sourcing, purification, and separation technologies for the Nuclear Medicine market
|
|
| Locked | Locked | Locked |
Devices and radioisotopes for nuclear imaging are provided by Niowave.
|
|
| Locked | Locked | Locked |
Multimodal visualization agents are developed for image-guided interventions.
|
|
| Locked | Locked | Locked |
Proprietary chemistry for pharmaceutical synthesis is developed by the company.
|
|
| Locked | Locked | Locked |
Limited information available
|
Detailed competitors of ARTMS
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Artms
Complete news archive for ARTMS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ARTMS
ARTMS was founded in 2013 and raised its 1st funding round 4 years after it was founded.
ARTMS is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Charles Conroy is the current CEO of ARTMS.
ARTMS is a funded company, having raised a total of $26.58M across 5 funding rounds to date.
ARTMS was founded in 2013 in Vancouver, Canada. The company operates in the radioisotope sector, where technologies for medical and research applications are developed. Services are extended to support radioisotope material creation by developers. The QIS system is utilized for turnkey production of purified radiometals. Focus is placed on enabling production processes within the healthcare isotope industry from a Canadian base.
ARTMS's top competitors include NorthStar Medical Radioisotopes, Niowave and ATOMIC ALCHEMY.
ARTMS has 5 investors. Key investors include GF Securities, Telix Pharmaceuticals, Innovate BC, Deerfield, and Quark Venture.